期刊
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
卷 191, 期 7, 页码 831-844出版社
AMER THORACIC SOC
DOI: 10.1164/rccm.201501-0044ST
关键词
-
资金
- Bayer
- Chiesi
- Takeda
- Vifor Pharma
- Forest
- MedImmune
- Respironics
- Spectral Diagnostics
- GlaxoSmithKline
- AstraZeneca-MedImmune
- Boehringer Ingelheim
- Sunovion Pharmaceuticals
- Cardif Assistance
- Vaincre la Mucoviscidose
- Almirall
- AstraZeneca
- Vertex
- Spiration
- Pearl
- Gilead
- Merck Sharp Dohme
- Mundipharma
- PneumRx
- Medical Acoustics
Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality, and resource use worldwide. The goal of this Official American Thoracic Society (ATS)/European Respiratory Society (ERS) Research Statement is to describe evidence related to diagnosis, assessment, and management; identify gaps in knowledge; and make recommendations for future research. It is not intended to provide clinical practice recommendations on COPD diagnosis and management. Methods: Clinicians, researchers, and patient advocates with expertise in COPD were invited to participate. A literature search of Medline was performed, and studies deemed relevant were selected. The search was not a systematic review of the evidence. Existing evidence was appraised and summarized, and then salient knowledge gaps were identified. Results: Recommendations for research that addresses important gaps in the evidence in all areas of COPD were formulated via discussion and consensus. Conclusions: Great strides have been made in the diagnosis, assessment, and management of COPD as well as understanding its pathogenesis. Despite this, many important questions remain unanswered. This ATS/ERS Research Statement highlights the types of research that leading clinicians, researchers, and patient advocates believe will have the greatest impact on patient-centered Outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据